Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
James N. Campbell
AddedMar 31, 2024
UpdatedMay 31, 2026
James N. Campbell

James N. Campbell

CEO, Arcion Therapeutics

CrunchbaseLinkedIn

James N. Campbell's Career

Arcion Therapeutics
Arcion Therapeutics

Baltimore, MD, US

CEO· C-Suite · Management
Centrexion Therapeutics
Centrexion Therapeutics

Boston, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

James N. Campbell's Career

Arcion Therapeutics
Arcion Therapeutics
Seed$17M142007Baltimore, MD, US
CEO· C-Suite · Management

Leadership at Arcion Therapeutics

Arnie OronskyArnie OronskyBoard Member
David J CollierDavid J CollierBoard Member
Dr Cynthia G McCormickDr Cynthia G McCormickBoard Member

Similar to Arcion Therapeutics

NeuroTherapeutics PharmaNeuroTherapeutics PharmaChicago, IL, USPharmaceuticals, Therapeuticsest. 2006NeuroTherapeutics PharmaChicago, IL, US · est. 2006

NeuroTherapeutics Pharma: A US-based biopharmaceutical firm specializing in neuropathic and acute pain treatments.

Public · $60.7M30
Arcuate TherapeuticsArcuate TherapeuticsBoston, MA, USPharmaceuticalsest. 2019Arcuate TherapeuticsBoston, MA, US · est. 2019

Boston-based pharmaceutical innovator, Arcuate Therapeutics, offers stealth healthcare solutions.

Series A · $5M5
4e Therapeutics4e TherapeuticsAustin, TX, USPain Therapiesest. 20194e TherapeuticsAustin, TX, US · est. 2019

4E Therapeutics innovates therapies for chronic neuropathic pain, migraine, and acute pain management.

Series A · $7.2M7
Nocion TherapeuticsNocion TherapeuticsWaltham, MA, USNeuron-Silencingest. 2017Nocion TherapeuticsWaltham, MA, US · est. 2017

Nocion Therapeutics: A biopharmaceutical firm innovating novel neuron-silencing treatments.

Series A · $49M17
Centrexion Therapeutics
Centrexion Therapeutics
Public$229.2M222013Boston, MA, US
Board Member· Board

Leadership at Centrexion Therapeutics

Kerrie BradyKerrie BradyFounder
Sol J. BarerSol J. BarerBoard Member
Joseph SwedishJoseph SwedishBoard Member
Jeffrey B. KindlerJeffrey B. KindlerCEO
Sara NayeemSara NayeemBoard Member
Stella XuStella XuBoard Member

Similar to Centrexion Therapeutics

Concentric AnalgesicsConcentric AnalgesicsSan Francisco, CA, USTherapeuticsest. 2014Concentric AnalgesicsSan Francisco, CA, US · est. 2014

Concentric Analgesics, Inc.: A biotech firm innovating non-opioid solutions for acute and chronic pain.

Series B · $103.1M22
TrigeminaTrigeminaMoraga, CA, USPain Treatmentsest. 2006TrigeminaMoraga, CA, US · est. 2006

Trigemina, Inc.: A US-based pharmaceutical company innovating non-opiate pain therapies.

Series A · $27.6M11
Tremeau PharmaceuticalsTremeau PharmaceuticalsConcord, MA, USPain Therapiesest. 2016Tremeau PharmaceuticalsConcord, MA, US · est. 2016

Massachusetts-based pharmaceutical company specializing in non-opioid pain therapies.

Private Equity · $115.2M11
Latigo BiotherapeuticsLatigo BiotherapeuticsThousand Oaks, CA, USDrug Developmentest. 2018Latigo BiotherapeuticsThousand Oaks, CA, US · est. 2018

Non-opioid drug developer providing unique therapies for chronic pain without addiction risks.

Series B · $15M18

James N. Campbell's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · Kakao

People Similar to James N. Campbell

Tj DunhamTj DunhamCo-Founder · ArcAntonio CarrilloAntonio CarrilloCEO · ArcosaJon DesalvoJon DesalvoCEO · ArcamedRami ElghandourRami ElghandourBoard Member · 3Degrees